Ata uhi

Design, Synthesis, and Evaluation of Oleyl-WRH Peptides for siRNA Delivery

Delivering nucleic acid therapeutics across cell membranes is a significant challenge. Cell-penetrating peptides (CPPs) containing arginine (R), tryptophan (W), and histidine (H) show promise for siRNA delivery. To improve siRNA delivery and silence a model STAT3 gene, we hypothesized that oleyl acy...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Mrigank Shekhar Rai (Author), Muhammad Imran Sajid (Author), Jonathan Moreno (Author), Keykavous Parang (Author), Rakesh Kumar Tiwari (Author)
Hōputu:	Pukapuka
I whakaputaina:	MDPI AG, 2024-08-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Oleyl Conjugated Histidine-Arginine Cell-Penetrating Peptides as Promising Agents for siRNA Delivery
mā: Muhammad Imran Sajid, me ētahi atu.
I whakaputaina: (2022)

Cyclic Peptide-Gadolinium Nanocomplexes as siRNA Delivery Tools
mā: Amir Nasrolahi Shirazi, me ētahi atu.
I whakaputaina: (2021)

Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside
mā: Muhammad Imran Sajid, me ētahi atu.
I whakaputaina: (2020)

Click-Free Synthesis of a Multivalent Tricyclic Peptide as a Molecular Transporter
mā: Sumit Kumar, me ētahi atu.
I whakaputaina: (2020)

Versatility of cell-penetrating peptides for intracellular delivery of siRNA
mā: Tejinder Singh, me ētahi atu.
I whakaputaina: (2018)

Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell Lines
mā: Dindyal Mandal, me ētahi atu.
I whakaputaina: (2023)

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
mā: Alexey Berezhnoy, me ētahi atu.
I whakaputaina: (2012)

Antibody-siRNA conjugates (ARC): Emerging siRNA drug formulation
mā: Weiran Cao, me ētahi atu.
I whakaputaina: (2022)

Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA
mā: Peter Järver, me ētahi atu.
I whakaputaina: (2012)

Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles
mā: Borja Ballarín-González, me ētahi atu.
I whakaputaina: (2013)

Dendrimers for siRNA Delivery
mā: Swati Biswas, me ētahi atu.
I whakaputaina: (2013)

Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics
mā: Mina Zare, me ētahi atu.
I whakaputaina: (2022)

Amphiphilic Cell-Penetrating Peptides Containing Arginine and Hydrophobic Residues as Protein Delivery Agents
mā: Jonathan Moreno, me ētahi atu.
I whakaputaina: (2023)

Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery
mā: Martina Tuttolomondo, me ētahi atu.
I whakaputaina: (2017)

Improved method for synthesis of low molecular weight protamine-siRNA conjugate
mā: Zhili Yu, me ētahi atu.
I whakaputaina: (2018)

Mechanistic Study of Antimicrobial Effectiveness of Cyclic Amphipathic Peptide [R<sub>4</sub>W<sub>4</sub>] against Methicillin-Resistant <i>Staphylococcus aureus</i> Clinical Isolates
mā: Ajayi David Akinwale, me ētahi atu.
I whakaputaina: (2024)

Drug Delivery of siRNA Therapeutics
I whakaputaina: (2020)

Transformative approaches for siRNA detection
mā: Sima Singh, me ētahi atu.
I whakaputaina: (2024)

Drug Delivery of siRNA Therapeutics
mā: Gaetano Lamberti, me ētahi atu.
I whakaputaina: (2020)

Cell-Penetrating Peptide and siRNA-Mediated Therapeutic Effects on Endometriosis and Cancer In Vitro Models
mā: Kristina Kiisholts, me ētahi atu.
I whakaputaina: (2021)

LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo
mā: Baptiste Broc, me ētahi atu.
I whakaputaina: (2024)

Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Plants, and Synthetic Sources
mā: Naiera M. Helmy, me ētahi atu.
I whakaputaina: (2023)

Cyclic Peptide-Gadolinium Nanoparticles for Enhanced Intracellular Delivery
mā: Amir Nasrolahi Shirazi, me ētahi atu.
I whakaputaina: (2020)

Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles
mā: Mahmoud S. Hanafy, me ētahi atu.
I whakaputaina: (2023)

siRNA Targeting and Treatment of Gastrointestinal Diseases
mā: Rachel Chevalier
I whakaputaina: (2019)

Bridging siRNA strands for better function
mā: John J. Rossi
I whakaputaina: (2023)

siRNA goes after diseases of the bone
mā: Andrew H. Coles
I whakaputaina: (2023)

Advances in Lipid Nanoparticles for siRNA Delivery
mā: Sam Chen, me ētahi atu.
I whakaputaina: (2013)

Transportan-derived cell-penetrating peptide delivers siRNA to inhibit replication of influenza virus in vivo
mā: Zhang C, me ētahi atu.
I whakaputaina: (2019)

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
mā: Nathan M Belliveau, me ētahi atu.
I whakaputaina: (2012)

Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery
mā: Zhao W, me ētahi atu.
I whakaputaina: (2016)

siRNA Versus miRNA as Therapeutics for Gene Silencing
mā: Jenny K W Lam, me ētahi atu.
I whakaputaina: (2015)

RNA binding protein as monodisperse carriers for siRNA delivery
mā: Wen Wang, me ētahi atu.
I whakaputaina: (2019)

Dendrimers Show Promise for siRNA and microRNA Therapeutics
mā: Volha Dzmitruk, me ētahi atu.
I whakaputaina: (2018)

cRGD peptide-conjugated polyethylenimine-based lipid nanoparticle for intracellular delivery of siRNA in hepatocarcinoma therapy
mā: Shuang Yang, me ētahi atu.
I whakaputaina: (2021)

Size Matters: Arginine-Derived Peptides Targeting the PSMA Receptor Can Efficiently Complex but Not Transfect siRNA
mā: Christopher N. Cultrara, me ētahi atu.
I whakaputaina: (2019)

Delivery Pathway Regulation of 3',3"-Bis-Peptide-siRNA Conjugate via Nanocarrier Architecture Engineering
mā: Jing Sun, me ētahi atu.
I whakaputaina: (2018)

Gene Therapy for Neuropathic Pain through siRNA-IRF5 Gene Delivery with Homing Peptides to Microglia
mā: Tomoya Terashima, me ētahi atu.
I whakaputaina: (2018)

In Vivo Follow-Up of Gene Inhibition in Solid Tumors Using Peptide-Based Nanoparticles for siRNA Delivery
mā: Isabel Ferreiro, me ētahi atu.
I whakaputaina: (2021)

siRNA Therapeutics: From Bench Lab. to Clinics
mā: Cristina Romero-López, me ētahi atu.
I whakaputaina: (2024)